Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VS011
- Development stage
- Unknown
- Lead developer
- Genfit
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VS011 is a small molecule therapeutic candidate being developed for the treatment of liver diseases, specifically targeting Acute-on-Chronic Liver Failure (ACLF). Developed by Versantis (which was acquired by Genfit in 2022), VS011 is designed as an orally available agent that aims to reduce systemic inflammation and prevent multi-organ failure by modulating metabolic pathways associated with liver dysfunction. While Versantis's lead asset VS-01 is a liposomal-based detoxification therapy administered via the peritoneum, VS011 represents a complementary approach in their pipeline focusing on oral delivery for chronic management or prevention of acute decompensation in cirrhotic patients.
Beyond the preview
Go deeper on VS011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VS011.